Abstract
Colorectal cancer (CRC) is one of the three most prevalent types of cancer (along with lung cancer and breast cancer) and the second most deadly cancer. The International Agency for Research on Cancer (IARC) estimates that in 2020, CRC was the cause of almost 1 million deaths worldwide. This work aims to review the available targeted therapeutic approaches in the treatment of metastatic CRC (mCRC), namely, monoclonal antibodies and inhibitors of protein kinases with therapeutic indication in mCRC. The databases of medicines for human use of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) were searched to identify targeted drugs with an approved indication for the treatment of mCRC. Within the scope of targeted therapies for the treatment of mCRC, ten drugs are currently available in the pharmaceutical market: a fusion protein with a mechanism of action that has similarities with monoclonal antibodies (aflibercept), seven monoclonal antibodies (bevacizumab, cetuximab, nivolumab + ipilimumab, panitumumab, pembrolizumab and ramucirumab), and two protein kinase inhibitors (encorafenib and regorafenib). An analysis was also carried out of the antineoplastic therapeutic regimens in which each of these drugs are included and their respective therapeutic indications. The high incidence and mortality of CRC require new therapeutic approaches, with proven efficacy and high levels of safety. Detailed study of the individual behavior of the tumor allows the use of targeted therapies, optimizing therapeutic results.
Similar content being viewed by others
References
International Agency for Research on Cancer WHO. Colorectal Cancer Awareness Month 2021 [Internet]. Int. Agency Res. Cancer, World Heal. Organ. Featur. News. 2021 [cited 2021 Aug 29]. https://www.iarc.who.int/featured-news/ccam2021/.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1):22.
Merck Europe B.V. Summary of Product Characteristics Erbitux® [Internet]. 2009. https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf.
Roche Registration GmbH. Summary of Product Characteristics Avastin® [Internet]. 2015. https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf.
Amgen Europe B.V. Summary of Product Characteristics Vectibix® [Internet]. 2019. https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf.
Sanofi-Aventis Groupe. Summary of Product Characteristics Zaltrap® [Internet]. 2017. https://www.ema.europa.eu/en/documents/product-information/zaltrap-epar-product-information_en.pdf.
Bayer AG. Summary of Product Characteristics Stivarga® [Internet]. 2018. https://www.ema.europa.eu/en/documents/product-information/stivarga-epar-product-information_en.pdf.
Eli Lilly Nederland B.V. Summary of Product Characteristics Cyramza® [Internet]. 2019. https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf.
Merck Sharp & Dohme B.V. Summary of Product Characteristics Keytruda® [Internet]. 2020. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf.
Bristol-Myers Squibb Pharma EEIG. Summary of Product Characteristics Opdivo® [Internet]. 2020. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf.
Bristol-Myers Squibb Pharma EEIG. Summary of Product Characteristics Yervoy® [Internet]. 2016. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf.
Pierre Fabre Médicament. Summary of Product Characteristics Braftovi® [Internet]. 2018. https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf.
Center for Drug Evaluation and Research (CDER) of the FDA. Application Number: 207981Orig1s000—Exclusivity Summary of Lonsurf® [Internet]. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000Admincorres.pdf.
Les Laboratoires Servier. Summary of Product Characteristics Lonsurf® [Internet]. 2016. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf.
Van Cutsem E, Köhne C-H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.
Qin S, Li J, Wang L, et al. Efficacy and tolerability of first-line cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with RAS wild-type metastatic colorectal cancer: the open-label, randomized, phase III TAILOR trial. J Clin Oncol. 2018;36:3031–9.
Pinto C, Di Fabio F, Rosati G, et al. Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study. Cancer Med. 2016;5:3272–81.
Françoso A, Simioni PU. Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. Drug Des Dev Ther. 2017;11:177–84.
Douillard J-Y, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–705.
Peeters M, Price TJ, Cervantes A, et al. Final results from a randomized phase 3 study of FOLFIRI +/- panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2014;25:107–16.
Hebart H, Kiehl M, Tomasek J, et al. Prospective observational cohort study to describe the use of panitumumab in combination with chemotherapy in real-world clinical practice for patients with wild-type RAS mCRC. Adv Ther. 2019;36:670–83.
Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91:1071–121.
Saif MW. Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? Cancer Manag Res. 2013;5:103–15.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.
Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14:1077–85.
Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306–15.
Pataky RE, Beca J, Tran D, et al. Real-world cost-effectiveness of bevacizumab with first-line combination chemotherapy in patients with metastatic colorectal cancer: population-based retrospective cohort studies in three Canadian provinces. MDM policy Pract. 2021;6(1):23814683211021060.
Wang F, Dai G, Deng Y, et al. Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: a prospective, multicenter, observational, non-interventional phase IV trial. Chin J Cancer Res. 2021;33:490–9.
Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–506.
Wang T-F, Lockhart AC. Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol. 2012;6:19–30.
Fernandez Montes A, Carlos López L, Carmona A, et al. Efficacy and toxicity results of FOLFIRI-Aflibercept in advanced colorectal cancer (CRCm) in “real life”, retrospective study. Prognostic factors and specific populations. Ann Oncol. 2017;28:iii103.
Ivanova JI, Saverno KR, Sung J, et al. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA. Med Oncol. 2017;34:193.
Fernández Montes A, Martínez Lago N, Covela Rúa M, et al. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: prognostic and predictive markers. Cancer Med. 2019;8:882–9.
Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin. Lancet Oncol. 2015;16:499–508.
Yoshihiro T, Kusaba H, Makiyama A, et al. Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. Int J Clin Oncol. 2019;24:508–15.
Suzuki T, Shinozaki E, Osumi H, et al. Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2019;84:307–13.
Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.
Giannakis M, Mu XJ, Shukla SA, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;15:857–65.
André T, Shiu K-K, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207–18.
Andre T, Shiu K-K, Kim TW, et al. Final overall survival for the phase III KN177 study: pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). J Clin Oncol. 2021;39:3500.
Ghaus A, Pheely A, Murdock V, et al. Real-world experience of pembrolizumab in microsatellite instability-high CRC: a Scottish multicenter analysis. J Clin Oncol. 2022;40:54–54.
Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–9.
Lam JJM, Bridgewater J, Alani M, et al. 502P Nivolumab, alone or with ipilimumab, for mismatch repair deficient metastatic colorectal cancer: a United Kingdom multicentre analysis of patient outcomes. Ann Oncol. 2020;31:S453.
Gotink KJ, Verheul HMW. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis. 2010;13:1–14.
Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315:971–9.
García-Aranda M, Redondo M. Targeting receptor kinases in colorectal cancer. Cancers (Basel). 2019;11(4):433.
Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12.
Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619–29.
Dhillon S. Regorafenib: a review in metastatic colorectal cancer. Drugs. 2018;78:1133–44.
Metges J-P, Genet D, Tougeron D, et al. Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort. Future Oncol. 2021;17:3343–53.
Kopeckova K, Buchler T, Bortlicek Z, et al. Regorafenib in the real-life clinical practice: data from the Czech registry. Target Oncol. 2017;12:89–95.
Lam K-O, Lee K-C, Chiu J, et al. The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong. Postgrad Med J. 2017;93:395–400.
Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381:1632–43.
Stintzing S, Hübner G, Schröder J, et al. P-58 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria—BERING CRC. Ann Oncol. 2021;32:S116.
Benson AB, Venook AP, Al-Hawary MM, et al. Colon Cancer, Version 2.2021, NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:329–59.
Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422.
Chiorean EG, Nandakumar G, Fadelu T, et al. Treatment of patients with late-stage colorectal cancer: ASCO Resource-Stratified Guideline. JCO Glob Oncol. 2020;6:414–38.
National Institute for Health and Care Excellence. Colorectal cancer—NICE guideline [NG151]. National Institute for Health and Care Excellence; 2021. https://www.nice.org.uk/guidance/ng151/resources/colorectal-cancer-pdf-66141835244485.
Cancer Council Australia Colorectal Cancer Guidelines Working Party. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer. Sydney: Cancer Council Australia 2018. https://wiki.cancer.org.au/australiawiki/index.php?oldid=213460.
Petrelli F, Ardito R, Ghidini A, et al. Different toxicity of cetuximab and panitumumab in metastatic colorectal cancer yreatment: a systematic review and meta-analysis. Oncology. 2018;94:191–9.
Sun D-C, Shi Y, Wang Y-R, et al. KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients. Sci Rep. 2017;7:14368.
Bui QL, Mas L, Hollebecque A, et al. Treatments after immune checkpoint inhibitors in patients with dMMR/MSI metastatic colorectal cancer. Cancers (Basel). 2022;14:406.
Lee JJ, Chu E. Recent Advances in the clinical development of immune checkpoint blockade therapy for mismatch repair proficient (pMMR)/non-MSI-H metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17:258–73.
Chu JE, Johnson B, Kugathasan L, et al. Population-based screening for BRAF V600E in metastatic colorectal cancer reveals increased prevalence and poor prognosis. Clin Cancer Res. 2020;26:4599–605.
Takeda H, Sunakawa Y. Management of BRAF gene alterations in metastatic colorectal cancer: from current therapeutic strategies to future perspectives. Front Oncol. 2021;11: 602194.
Tabernero J, Velez L, Trevino TL, et al. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO Open. 2021;6: 100328.
Bajwa R, Cheema A, Khan T, et al. Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study. J Clin Med Res. 2019;11:225–36.
Morgado M, Plácido A, Morgado S, et al. Management of the adverse effects of immune checkpoint inhibitors. Vaccines [Internet]. 2020;8(4):575.
Pottier C, Fresnais M, Gilon M, et al. Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy. Cancers (Basel). 2020;12(3):731.
Yajima S, Shimizu H, Sakamaki H, et al. Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy. BMC Health Serv Res. 2015;16:2.
Zhang B, Fang C, Deng D, et al. Research progress on common adverse events caused by targeted therapy for colorectal cancer. Oncol Lett. 2018;16(1):27–33.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No research funding.
Conflict of interest
Sandra Morgado, Mafalda Silva, Olímpia Fonseca, Fátima Roque, and Manuel Morgado state that they have no conflicts of interest regarding the publication of this article.
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Availability of data and material
Not applicable.
Code availability
Not applicable.
Author contributions
Sandra Morgado acquisition, analysis, and interpretation of data, drafting of the manuscript and critical revision of the manuscript for important intellectual content. Mafalda Silva acquisition, analysis, and interpretation of data, drafting of the manuscript and technical support. Olímpia Fonseca and Fátima Roque critical revision of the manuscript for important intellectual content. Manuel Morgado concept and study design, acquisition, analysis, and interpretation of data and critical revision of the manuscript for important intellectual content.
Rights and permissions
About this article
Cite this article
Morgado, S., Silva, M., Fonseca, O. et al. Targeted therapy for metastatic colorectal cancer: what do we currently have in clinical practice?. Drugs Ther Perspect 38, 222–234 (2022). https://doi.org/10.1007/s40267-022-00915-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-022-00915-9